SPDR® S&P Biotech ETF
(NYSE ARCA: XBI)
AdChoices
166.52
+1.36
+0.82%
:

Open

165.32

Net Assets

1.30B

Day's Range

164.60-167.41

52 week range

114.12-172.52

Category

Health

Vol (3-Month Avg.)

388.46k

Yield

0.99%

Morningstar Risk

High

AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Key Statistics
Composition
Top Equity Sector Holding
Equity Investment Style
The two dimensions of the Fund Style box measure the average size of companies that have been in the ETF, from the top to bottom, and the average valuation characteristics of the ETF's past stock holdings, from left to right.

PERFORMANCE

  • Total Return %

  • 1 Day

  • 1 Week

  • 1 Month

  • 3 Months

  • 1 Year

  • 3 Years

  • 5 Years

    • XBI

    • -0.91

    • 4.63

    • 2.53

    • 13.63

    • 32.05

    • 35.52

    • 26.26

    • Category(Health)

    • 1.83

    • 6.34

    • 1.61

    • 5.15

    • 27.17

    • 29.48

    • 23.14

    • Rank in Category

    • 75

    • 40

    • 1

    • 5

    • 25

    • 16

    • 20

    MORNINGSTAR RATING

    • Years

    • Return

    • Risk

    • Rating

      • 3 Years

      • Above Average

      • High

      • ★★★
      • 5 Years

      • Above Average

      • High

      • ★★
      • 10 Years

      • -

      • -

      • -

      • Overall

      • Above Average

      • High

      • ★★

      TOP HOLDINGS

      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Agios Pharmaceuticals Inc

        • 2.14

        • 354,039

        • -6,960

        • NewLink Genetics Corp

        • 1.76

        • 570,460

        • -11,223

        • AMAG Pharmaceuticals Inc

        • 1.64

        • 613,165

        • -12,033

        • Repligen Corp

        • 1.59

        • 838,233

        • -16,446

        • Alnylam Pharmaceuticals Inc

        • 1.57

        • 215,817

        • -4,239

        • Merrimack Pharmaceuticals Inc

        • 1.55

        • 2,153,777

        • -42,276

        • Clovis Oncology Inc

        • 1.45

        • 339,826

        • -6,666

        • Vertex Pharmaceuticals Inc

        • 1.44

        • 168,377

        • -3,309

        • PTC Therapeutics Inc

        • 1.44

        • 478,549

        • -9,387

        • Keryx Biopharmaceuticals Inc

        • 1.43

        • 1,091,875

        • -21,420

        CATEGORY

        • Name

        • XBI

        • Category

          • Avg. Market Cap USD (M)

          • 1,930.16

          • 27,214.31

          • Expense Ratio

          • 0.35%

          • 0.44%

          • Net Assets

          • 1.30B

          • 1.06B

          • Price/Prospective Earnings

          • 38.60

          • 21.83

          • Price/Book

          • 4.24

          • 4.82

          • Price/Sales

          • 9.75

          • 3.25

          • Price/Cash Flow

          • 4.41

          • 19.29

          • Dividend Yield

          • 0.03%

          • 0.03

          Profile

          Name of Issuer

          SPDR State Street Global Advisors

          Expenses

          0.35%

          The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

          Inception

          1/31/2006